新型抗黑色素瘤治疗:以免疫疗法为重点。

Q Medicine

癌症 Pub Date : 2014-09-01 DOI:10.5732/cjc.014.10118

Meng-Ze Hao, Wen-Ya Zhou, Xiao-Ling Du, Ke-Xin Chen, Guo-Wen Wang, Yun Yang, Ji-Long Yang

{"title":"新型抗黑色素瘤治疗:以免疫疗法为重点。","authors":"Meng-Ze Hao, Wen-Ya Zhou, Xiao-Ling Du, Ke-Xin Chen, Guo-Wen Wang, Yun Yang, Ji-Long Yang","doi":"10.5732/cjc.014.10118","DOIUrl":null,"url":null,"abstract":"Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New approaches to managing this deadly disease are much anticipated to enhance the cure rate and to extend clinical benefits to patients with metastatic melanoma. Due to its high degree of immunogenicity, melanoma could be a good target for immunotherapy, which has been developed for decades and has achieved certain progress. This article provides an overview of immunotherapy for melanoma. ","PeriodicalId":10034,"journal":{"name":"癌症","volume":"33 9","pages":"458-65"},"PeriodicalIF":0.0000,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/80/cjc-33-09-458.PMC4190435.pdf","citationCount":"12","resultStr":"{\"title\":\"Novel anti-melanoma treatment: focus on immunotherapy.\",\"authors\":\"Meng-Ze Hao, Wen-Ya Zhou, Xiao-Ling Du, Ke-Xin Chen, Guo-Wen Wang, Yun Yang, Ji-Long Yang\",\"doi\":\"10.5732/cjc.014.10118\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New approaches to managing this deadly disease are much anticipated to enhance the cure rate and to extend clinical benefits to patients with metastatic melanoma. Due to its high degree of immunogenicity, melanoma could be a good target for immunotherapy, which has been developed for decades and has achieved certain progress. This article provides an overview of immunotherapy for melanoma. \",\"PeriodicalId\":10034,\"journal\":{\"name\":\"癌症\",\"volume\":\"33 9\",\"pages\":\"458-65\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/80/cjc-33-09-458.PMC4190435.pdf\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"癌症\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5732/cjc.014.10118\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5732/cjc.014.10118","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 12

摘要

黑色素瘤是一种具有侵袭性、致命性和转移性的顽固性癌症。晚期黑色素瘤的预后非常差，因为它对化疗和放疗不敏感。近年来，黑素瘤的发病率在全球范围内稳步上升，死亡率也在不断上升。治疗这种致命疾病的新方法有望提高治愈率，并扩大转移性黑色素瘤患者的临床获益。黑色素瘤具有高度的免疫原性，是免疫治疗的一个很好的靶点，经过几十年的发展，已经取得了一定的进展。本文综述了黑色素瘤的免疫治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Novel anti-melanoma treatment: focus on immunotherapy.

Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New approaches to managing this deadly disease are much anticipated to enhance the cure rate and to extend clinical benefits to patients with metastatic melanoma. Due to its high degree of immunogenicity, melanoma could be a good target for immunotherapy, which has been developed for decades and has achieved certain progress. This article provides an overview of immunotherapy for melanoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

癌症 ONCOLOGY-

CiteScore

3.47

自引率

0.00%

发文量

9010

审稿时长

12 weeks

期刊介绍： In July 2008, Landes Bioscience and Sun Yat-sen University Cancer Center began co-publishing the international, English-language version of AI ZHENG or the Chinese Journal of Cancer (CJC). CJC publishes original research, reviews, extra views, perspectives, supplements, and spotlights in all areas of cancer research. The primary criteria for publication in CJC are originality, outstanding scientific merit, and general interest. The Editorial Board is composed of members from around the world, who will strive to maintain the highest standards for excellence in order to generate a valuable resource for an international readership.